Anzeige
Mehr »
Sonntag, 31.08.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QQJB | ISIN: US52886N4060 | Ticker-Symbol:
NASDAQ
29.08.25 | 22:00
0,883 US-Dollar
-0,81 % -0,007
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
LEXARIA BIOSCIENCE CORP Chart 1 Jahr
5-Tage-Chart
LEXARIA BIOSCIENCE CORP 5-Tage-Chart

Aktuelle News zur LEXARIA BIOSCIENCE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiLexaria Bioscience Corp.: Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference199KELOWNA, BC / ACCESS Newswire / August 27, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that...
► Artikel lesen
14.08.Lexaria completes patient dosing in GLP-1 study, final results expected Q42
LEXARIA BIOSCIENCE Aktie jetzt für 0€ handeln
14.08.Lexaria Bioscience stock rises after completion of GLP-1 study milestone2
14.08.Lexaria Bioscience Corp.: Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone292KELOWNA, BC / ACCESS Newswire / August 14, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce...
► Artikel lesen
06.08.Lexaria Bioscience Corp.: GLP-1 "Arms Race" Broadens to Include Dozens of Companies314Lexaria highlights DehydraTECH's adverse events improvement opportunity KELOWNA, BC / ACCESS Newswire / August 6, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria")...
► Artikel lesen
29.07.H.C. Wainwright senkt Kursziel für Lexaria Bioscience wegen Aktienverwässerung1
29.07.H.C. Wainwright lowers Lexaria Bioscience stock price target on share dilution2
28.07.Lexaria Bioscience Corp.: Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study718DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus®DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus®DehydraTECH-GLP-1...
► Artikel lesen
23.07.Lexaria's DehydraTECH reduces side effects in GLP-1 drugs4
23.07.Lexaria Bioscience Corp.: Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry283The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted side effectsDehydraTECH reduces side effects and could support patient retention...
► Artikel lesen
14.07.Lexaria Bioscience Corp. - 10-Q, Quarterly Report1
01.07.Kursziel für Lexaria Bioscience von H.C. Wainwright auf 5 US-Dollar gesenkt2
01.07.Lexaria Bioscience stock price target lowered to $5 at H.C. Wainwright1
23.06.Lexaria Bioscience expands patent portfolio to 50 with new additions5
23.06.Lexaria Bioscience Corp.: Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide225New patents received for the treatment of epilepsy and for the sublingual delivery of nicotine KELOWNA, BC / ACCESS Newswire / June 23, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the...
► Artikel lesen
12.06.Lexaria Bioscience Corp. - 8-K, Current Report2
11.06.Lexaria Bioscience Corp.: Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule276Oral DehydraTECH-liraglutide showed a pronounced reduction in adverse events ("AEs") as compared to injected liraglutide (Saxenda(R)) Lexaria has now demonstrated, in distinct human clinical studies...
► Artikel lesen
05.06.Lexaria Bioscience Corp.: Lexaria Attending BIO International Convention264Biotechnology Sector's Premier Strategic Partnering Event KELOWNA, BC / ACCESS Newswire / June 5, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator...
► Artikel lesen
12.05.Lexaria advances drug delivery tech with PharmaCO2
12.05.Lexaria Bioscience Corp.: Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company884KELOWNA, BC / ACCESS Newswire / May 12, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this update on corporate...
► Artikel lesen
Weiter >>
68 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1